Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Sector Update: Consumer Stocks Decline Premarket Tuesday

Sector Update: Consumer Stocks Decline Premarket Tuesday

MT newswireMT newswire2026/09/29 13:13
09:13 AM EDT, 09/29/2026 (MT Newswires) -- Consumer stocks were declining premarket Tuesday, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) down 0.5% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) 0.2% lower. British American Tobacco (BTI) continues to expect 2026 adjusted earnings per share growth towards the middle of its outlook range of 5% to 8% at constant exchange rates, the company said. Shares of British American Tobacco were down more than 1% pre-bell. CarMax (KMX) stock was up more than 6% after the company reported higher fiscal Q2 net earnings and net sales, and unveiled plans to resume share repurchases at "a modest level" in fiscal Q3. Wyndham Hotels & Resorts' (WH) board has approved a $400 million increase to the company's share repurchase authorization, the company said. Wyndham Hotels & Resorts shares were up more than 3% premarket.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Why did the Reserve Bank of Australia raise interest rates two weeks ago? Meeting minutes reveal inflation risks have become a reality, and waiting would be too costly

The Reserve Bank of Australia acknowledges that the trade-off between inflation and full employment has worsened, but maintains that its goal is to return the Consumer Price Index (CPI) to the 2-3% target range.

智通财经•2026/10/13 02:41

Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results

Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.

智通财经•2026/10/13 01:56